Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Follow-Up Questions
What is the price performance of LUCD stock?
The current price of LUCD is $1.19, it has increased 0.84% in the last trading day.
What are the primary business themes or industries for Lucid Diagnostics Inc?
Lucid Diagnostics Inc belongs to Health Care industry and the sector is Health Care
What is Lucid Diagnostics Inc market cap?
Lucid Diagnostics Inc's current market cap is $158.8M
Is Lucid Diagnostics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Lucid Diagnostics Inc, including 3 strong buy, 8 buy, 1 hold, 0 sell, and 3 strong sell
